Aldo H de la Cruz-Montoya

Dr. Aldo H de la Cruz-Montoya

UNAM FES Iztacala
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
MMMayeli M. Martínez-Aguilar
Mayeli M. Martínez-Aguilar
DADiana I. Aparicio-Bautista
Diana I. Aparicio-Bautista
EREric Ramirez-Salazar
Eric Ramirez-Salazar
JRJuan Pablo Reyes-Grajeda
Juan Pablo Reyes-Grajeda
Aldo H de la Cruz-MontoyaAldo H de la Cruz-Montoya
Aldo H de la Cruz-Montoya
RVRafael Velazquez-Cruz
Rafael Velazquez-Cruz
Osteoporosis is a skeletal disease mainly affecting women over 50 years old and it represents a serious public health problem because of the high socioeconomic burden. This disease is characterized by deterioration of bone microarchitecture, low bone mineral density (BMD), and increased risk of fragility fractures. This study aimed to identify serum useful proteins as biomarkers for the diagnosis and/or prognosis of osteoporosis and fracture risk. We collected 446 serum samples from postmenopausal women aged ≥45 years old. Based on the BMD measurement, we classified the participants into three groups: osteoporotic, osteopenic, and normal. In an initial discovery stage, we conducted a proteomic approach using two-dimensional differential gel electrophoresis (2D-DIGE). The peptides into the spots of interest were identified through matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF/TOF). Enzyme-linked immunosorbent assay (ELISA) was performed to validate the proteins of interest. We identified 27 spots of interest when comparing low BMD versus normal BMD postmenopausal women. Based on their relevance in bone metabolism, we analyzed three proteins: ceruloplasmin (CP), gelsolin (GSN), and vitamin D-binding protein (VDBP). Our results demonstrated that low serum VDBP levels correlate with low BMD (osteopenic and osteoporotic). Therefore, VDBP could be considered as a novel, potential, and non-invasive biomarker for the early detection of osteoporosis.

14 June 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
BRBerenice Rivera-Paredez
Berenice Rivera-Paredez
LMLuis Rodrigo Macias
Luis Rodrigo Macias
Juan Carlos Fernandez-LopezJuan Carlos Fernandez-Lopez
Juan Carlos Fernandez-Lopez
MVMarisela Villalobos-Comparán
Marisela Villalobos-Comparán
MMMayeli M. Martinez-Aguilar
Mayeli M. Martinez-Aguilar
RVRafael Velazquez-Cruz
Rafael Velazquez-Cruz
Risk of hyperuricemia is modified by genetic and environmental factors. Our aim was to identify factors associated with serum uric acid levels and hyperuricemia in Mexicans. A pilot Genome-wide association study GWAS was performed in a subgroup of participants (n = 411) from the Health Workers Cohort Study (HWCS). Single nucleotide polymorphisms (SNPs) associated with serum uric acid levels were validated in all the HWCS participants (n = 1939) and replicated in independent children (n = 1080) and adult (n = 1073) case-control studies. The meta-analysis of the whole HWCS and replication samples identified three SLC2A9 SNPs: rs1014290 (p = 2.3 × 10−64), rs3775948 (p = 8.2 × 10−64) and rs11722228 (p = 1.1 × 10−17); and an ABCG2 missense SNP, rs2231142 (p = 1.0 × 10−18). Among the non-genetic factors identified, the visceral adiposity index, smoking, the metabolic syndrome and its components (waist circumference, blood pressure, glucose and hyperlipidemia) were associated with increased serum uric acid levels and hyperuricemia (p < 0.05). Among the female HWCS participants, the odds ratio for hyperuricemia was 1.24 (95% CI, 1.01–1.53) per unit increase in soft drink consumption. As reported in other studies, our findings indicate that diet, adiposity and genetic variation contribute to the elevated prevalence of hyperuricemia in Mexico.

19 June 2024 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
MCMiguel Ruiz De La Cruz
Miguel Ruiz De La Cruz
HMHécTor MartínEz-Gregorio
HécTor MartínEz-Gregorio
CDClara Estela DíaZ-VelásQuez
Clara Estela DíaZ-VelásQuez
FAFernando Ambriz-Barrera
Fernando Ambriz-Barrera
NRNorma Gabriela Resendiz-Flores
Norma Gabriela Resendiz-Flores
FPFelipe Vaca Paniagua
Felipe Vaca Paniagua
Less than 15–20% of patients who meet the criteria for hereditary breast and ovarian cancer (HBOC) carry pathogenic coding genetic mutations, implying that other molecular mechanisms may contribute to the increased risk of this condition. DNA methylation in peripheral blood has been suggested as a potential epigenetic marker for the risk of breast cancer (BC). We aimed to discover methylation marks in peripheral blood associated with BC in 231 pre-treatment BC patients meeting HBOC criteria, testing negative for coding pathogenic variants, and 156 healthy controls, through methylation analysis by targeted bisulfite sequencing on 18 tumor suppressor gene promoters (330 CpG sites). We found i) hypermethylation in EPCAM (17 CpG sites; p = 0.017) and RAD51C (27 CpG sites; p = 0.048); ii) hypermethylation in 36 CpG-specific sites (FDR q < 0.05) in the BC patients; iii) four specific CpG sites were associated with a higher risk of BC (FDR q < 0.01, Bonferroni p < 0.001): cg89786999-FANCI (OR = 1.65; 95% CI:1.2–2.2), cg23652916-PALB2 (OR = 2.83; 95% CI:1.7–4.7), cg47630224-MSH2 (OR = 4.17; 95% CI:2.1–8.5), and cg47596828-EPCAM (OR = 1.84; 95% CI:1.5–2.3). Validation of cg47630224-MSH2 methylation in one Australian cohort showed an association with 3-fold increased BC risk (AUC: 0.929; 95% CI: 0.904–0.955). Our findings suggest that four DNA methylation CpG sites may be associated with a higher risk of BC, potentially serving as biomarkers in patients without detectable coding mutations.

26 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MCMiguel Ruiz De La Cruz
Miguel Ruiz De La Cruz
Aldo H de la Cruz-MontoyaAldo H de la Cruz-Montoya
Aldo H de la Cruz-Montoya
ERErnesto Rojas-Jiménez
Ernesto Rojas-Jiménez
HGHéctor Martínez Gregorio
Héctor Martínez Gregorio
CVClara Estela Díaz Velásquez
Clara Estela Díaz Velásquez
FPFelipe Vaca Paniagua
Felipe Vaca Paniagua
Epigenetics affects gene expression and contributes to disease development by alterations known as epimutations. Hypermethylation that results in transcriptional silencing of tumor suppressor genes has been described in patients with hereditary cancers and without pathogenic variants in the coding region of cancer susceptibility genes. Although somatic promoter hypermethylation of these genes can occur in later stages of the carcinogenic process, constitutional methylation can be a crucial event during the first steps of tumorigenesis, accelerating tumor development. Primary epimutations originate independently of changes in the DNA sequence, while secondary epimutations are a consequence of a mutation in a cis or trans-acting factor. Secondary epimutations have a genetic basis in cis of the promoter regions of genes involved in familial cancers. This highlights epimutations as a novel carcinogenic mechanism whose contribution to human diseases is underestimated by the scarcity of the variants described. In this review, we provide an overview of secondary epimutations and present evidence of their impact on cancer. We propose the necessity for genetic screening of loci associated with secondary epimutations in familial cancer as part of prevention programs to improve molecular diagnosis, secondary prevention, and reduce the mortality of these diseases.

12 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HGHéctor Martínez Gregorio
Héctor Martínez Gregorio
ERErnesto Rojas-Jiménez
Ernesto Rojas-Jiménez
JMJavier César Mejía-Gómez
Javier César Mejía-Gómez
CDClara Díaz-Velásquez
Clara Díaz-Velásquez
RURosalia Quezada Urban
Rosalia Quezada Urban
FPFelipe Vaca Paniagua
Felipe Vaca Paniagua
In triple-negative breast cancer (TNBC), only 30% of patients treated with neoadjuvant chemotherapy achieve a pathological complete response after treatment and more than 90% die due to metastasis formation. The diverse clinical responses and metastatic developments are attributed to extensive intrapatient genetic heterogeneity and tumor evolution acting on this neoplasm. In this work, we aimed to evaluate genomic alterations and tumor evolution in TNBC patients with aggressive disease. We sequenced the whole exome of 16 lesions from four patients who did not respond to therapy, and took several follow-up samples, including samples from tumors before and after treatment, as well as from the lymph nodes and skin metastases. We found substantial intrapatient genetic heterogeneity, with a variable tumor mutational composition. Early truncal events were MCL1 amplifications. Metastatic lesions had deletions in RB1 and PTEN, along with TERT, AKT2, and CCNE1 amplifications. Mutational signatures 06 and 12 were mainly detected in skin metastases and lymph nodes. According to phylogenetic analysis, the lymph node metastases occurred at an early stage of TNBC development. Finally, each patient had three to eight candidate driving mutations for targeted treatments. This study delves into the genomic complexity and the phylogenetic and evolutionary development of aggressive TNBC, supporting early metastatic development, and identifies specific genetic alterations associated with a response to targeted therapies.

1 September 2018 in Experimental Biology and Medicine
Verified
Journal Article
Open access
PDF file
Aldo H de la Cruz-MontoyaAldo H de la Cruz-Montoya
Aldo H de la Cruz-Montoya
EREric Ramirez-Salazar
Eric Ramirez-Salazar
MMMayeli M. Martínez-Aguilar
Mayeli M. Martínez-Aguilar
PGPablo M. González-De-La-Rosa
Pablo M. González-De-La-Rosa
MQManuel Quiterio
Manuel Quiterio
RVRafael Velázquez-Cruz
Rafael Velázquez-Cruz
Osteoporosis is the most frequent disorder of bone metabolism, owing to an alteration between osteoclast and osteoblast activity, which results from the interaction of genetic, environmental, and epigenetic factors. microRNAs, small non-coding RNAs of around 22 nucleotides with important regulatory roles in gene regulation, that target mRNAs for post-transcriptional destabilization have been suggested as biomarkers in several disorders. In this work, we used small RNA sequencing to identify microRNAs from peripheral blood monocytes that were differentially expressed between non-osteoporotic and osteoporotic Mexican postmenopausal women, to elucidate the potential role of microRNAs as non-invasive marker candidates in osteoporosis. We identified six candidate microRNAs: four were up-regulated (miR-708-5p, miR-34b-5p, miR-3161, miR-328-5p), while two were down-regulated (miR-4422 and miR-939-3p) in osteoporotic women. Differential expression was validated by quantitative RT-PCR and only the upregulation of miR-708-5p was found to be statistically significant. Bioinformatic analysis of target genes for miR-708-5p showed 15 signaling pathways related to bone metabolism. Since monocytes are osteoclast precursors, 10 potential target genes present in these pathways and related to osteoclastogenesis were identified (AKT1, AKT2, CCND1, PARP1, SMAD3, CXCL5, FKBP5, MAP2K3, MMP2, and IKBKG). Five of them were found to be down-regulated according to microarray expression data. This is the first time that miR-708-5p has been identified in peripheral blood monocytes and associated with postmenopausal osteoporosis. Our results suggest that miR-708-5p reduces the expression of AKT1, AKT2, PARP1 FKBP5, and MP2K3 in peripheral blood monocytes contributing to an osteoporotic phenotype and could be a candidate marker for postmenopausal osteoporosis in Mexican population.